{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Atorvastatin&page=5", "query": { "intervention": "Placebo, Atorvastatin", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 139, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Atorvastatin&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Atorvastatin&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T08:38:46.440Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01617655", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2012-06", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 14, "location_summary": "Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01617655" }, { "nct_id": "NCT00616772", "title": "Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease", "Coronary Heart Disease", "Dyslipidemia" ], "interventions": [ { "name": "ABT-335", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Atorvastatin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 682, "start_date": "2008-02", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 124, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 67 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00616772" }, { "nct_id": "NCT01071993", "title": "Efficacy of Statins In Prevention of CIN", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nephropathy" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 21, "start_date": "2010-03", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2017-12-04", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 2, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01071993" }, { "nct_id": "NCT05028829", "title": "Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Fibroses", "Cirrhosis" ], "interventions": [ { "name": "Atorvastatin 20mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Raymond Chung", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-05-10", "completion_date": "2031-03-01", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Dallas, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05028829" }, { "nct_id": "NCT00412113", "title": "A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dyslipidemia", "Hypertension" ], "interventions": [ { "name": "Amlodipine besylate", "type": "DRUG" }, { "name": "Amlodipine besylate/atorvastatin calcium single pill combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 245, "start_date": "2007-01", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412113" }, { "nct_id": "NCT01105975", "title": "A Study of LY2484595 in Patients With High LDL-C or Low HDL-C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "LY2484595", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo for LY2484595", "type": "DRUG" }, { "name": "Placebo for Statins", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2010-04", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2018-03-22", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 38, "location_summary": "Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Vista", "state": "California" }, { "city": "Golden", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01105975" }, { "nct_id": "NCT02603328", "title": "Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cerebral Cavernous Malformation" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2018-07-17", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603328" }, { "nct_id": "NCT06157099", "title": "Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIB Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-09-01", "completion_date": "2029-09-01", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06157099" }, { "nct_id": "NCT02714569", "title": "A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dyslipidemias" ], "interventions": [ { "name": "LY3202328", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2016-03", "completion_date": "2017-02-15", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 4, "location_summary": "Miami, Florida • Lenexa, Kansas • Marlton, New Jersey + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02714569" }, { "nct_id": "NCT01186289", "title": "Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neurocognitive Dysfunction" ], "interventions": [ { "name": "atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 0, "start_date": "2010-10", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-10-11T08:38:46.440Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186289" } ] }